Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Problems with China Trial Data of BMS/Pfizer Blood Thinner Caused Delay in Approval

publication date: Jul 9, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
China promotes itself as a great place to conduct global clinical trials. It features low costs and the world’s largest population, most of whom are treatment naïve. But according to documents recently released by the US FDA, the China arm of a global trial caused a nine-month delay in the approval process of Eliquis, a major new product. The reason? There were errors in the data, the wrong drugs may have been administered and adverse events were covered up. More details....

Stock Symbols: (NYSE: BMY) (NYSE: PFE)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...